Mathias Falcenberg, PhD
Mathias joined Forbion as Analyst in 2016 and is located in the Munich Office.
Before, he was project leader for metabolic therapy at the Max Planck Institute of Biochemistry (MPIB) responsible for international and multi-disciplinary R&D collaborations as well as supervising a research team to investigate GRK5 signaling in diabetes and cancer. He did his PhD in Prof. Dr. Axel Ullrichs department at the MPIB investigating sutent-sensitive kinases as targets for novel anti-diabetic therapy development. During his time at the MPIB he managed the scientific implementation of a joint venture with Glaxo-Smith-Kline to find novel active ingredient candidates for the treatment of type 2 diabetes. Based on his own scientific findings, which led to four patents, he was involved in spin-out activities as designated co-founder since 2013. At Forbion, Mathias supports the scientific evaluation of investment opportunities and due diligence.